[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BG106046A - Фармацевтични състави на еритропоетин - Google Patents

Фармацевтични състави на еритропоетин

Info

Publication number
BG106046A
BG106046A BG106046A BG10604601A BG106046A BG 106046 A BG106046 A BG 106046A BG 106046 A BG106046 A BG 106046A BG 10604601 A BG10604601 A BG 10604601A BG 106046 A BG106046 A BG 106046A
Authority
BG
Bulgaria
Prior art keywords
ertythropoietin
pharmaceutical compositions
erythropoietin
amino acid
pharmaceutical formulations
Prior art date
Application number
BG106046A
Other languages
English (en)
Inventor
Wing Cheung
Jaya Natarajan
Marilyn Sanders
Els Vercammen
Selima Begum
Basant Sharma
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of BG106046A publication Critical patent/BG106046A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до водни фармацевтични форми на еритропоетин, свободни от продукти на човешкия кръвен серум, стабилизирани с определено количество аминокиселина и производно на сорбитан моно-9-октадеценоат поли(окси-1,2-етандиил). Изобретението се отнася и до водоустойчиви, стабилизирани фармацевтични форми на епитропоетин, които съдържат определено антимикробно количество крезол и определено количество аминокиселина.
BG106046A 1999-04-09 2001-10-24 Фармацевтични състави на еритропоетин BG106046A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12859699P 1999-04-09 1999-04-09
PCT/US2000/009414 WO2000061169A1 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin
US09/545,479 US6696056B1 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin

Publications (1)

Publication Number Publication Date
BG106046A true BG106046A (bg) 2002-05-31

Family

ID=22436082

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106046A BG106046A (bg) 1999-04-09 2001-10-24 Фармацевтични състави на еритропоетин

Country Status (27)

Country Link
US (2) US6696056B1 (bg)
EP (1) EP1181036B1 (bg)
JP (1) JP2002541208A (bg)
KR (1) KR100740794B1 (bg)
CN (1) CN1165339C (bg)
AR (1) AR029623A1 (bg)
AT (1) ATE401908T1 (bg)
AU (1) AU775041B2 (bg)
BG (1) BG106046A (bg)
BR (1) BR0010665A (bg)
CA (1) CA2369444C (bg)
CY (1) CY1108418T1 (bg)
DE (1) DE60039598D1 (bg)
DK (1) DK1181036T3 (bg)
ES (1) ES2308978T3 (bg)
HK (1) HK1041445B (bg)
HU (1) HUP0201068A3 (bg)
IL (1) IL145816A0 (bg)
MX (1) MXPA01010208A (bg)
NO (1) NO20014893L (bg)
NZ (1) NZ515380A (bg)
PL (1) PL203797B1 (bg)
PT (1) PT1181036E (bg)
RU (1) RU2225221C2 (bg)
TR (1) TR200103788T2 (bg)
WO (1) WO2000061169A1 (bg)
ZA (1) ZA200109236B (bg)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
KR100740794B1 (ko) * 1999-04-09 2007-07-20 오르토-맥네일 파마슈티칼, 인코퍼레이티드 에리트로포이에틴의 약제학적 제형
US7371787B2 (en) * 2000-04-14 2008-05-13 Viance, Llc Methods of incorporating treatment agents into wood based composite products
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2004244920B2 (en) 2003-06-10 2009-07-23 Lg Chem, Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
WO2007037795A2 (en) * 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US8796206B2 (en) * 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100956431B1 (ko) 2007-12-07 2010-05-06 주식회사 제이에스마루 혈장크린접착제 및 이의 제조방법
JP5694171B2 (ja) 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
CN109982685B (zh) 2016-10-21 2022-03-11 美国安进公司 药物配制品及其制备方法
CA3065540A1 (en) * 2017-06-06 2018-12-13 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5543575A (en) * 1990-06-20 1996-08-06 Pioneer-Hi-Bred International, Inc. Inbred corn line PHK46
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
KR100740794B1 (ko) * 1999-04-09 2007-07-20 오르토-맥네일 파마슈티칼, 인코퍼레이티드 에리트로포이에틴의 약제학적 제형

Also Published As

Publication number Publication date
CA2369444A1 (en) 2000-10-19
EP1181036A4 (en) 2004-04-21
CN1165339C (zh) 2004-09-08
AU775041B2 (en) 2004-07-15
TR200103788T2 (tr) 2002-05-21
NO20014893D0 (no) 2001-10-08
PL351837A1 (en) 2003-06-16
KR100740794B1 (ko) 2007-07-20
NO20014893L (no) 2001-11-15
DE60039598D1 (de) 2008-09-04
HK1041445A1 (en) 2002-07-12
HUP0201068A2 (en) 2002-08-28
CN1354669A (zh) 2002-06-19
MXPA01010208A (es) 2003-07-21
HK1041445B (zh) 2009-07-03
ES2308978T3 (es) 2008-12-16
US6696056B1 (en) 2004-02-24
HUP0201068A3 (en) 2002-10-28
ATE401908T1 (de) 2008-08-15
PL203797B1 (pl) 2009-11-30
BR0010665A (pt) 2004-03-09
KR20020016770A (ko) 2002-03-06
CY1108418T1 (el) 2014-04-09
US20040248797A1 (en) 2004-12-09
ZA200109236B (en) 2003-12-08
EP1181036B1 (en) 2008-07-23
AU4218600A (en) 2000-11-14
WO2000061169A1 (en) 2000-10-19
IL145816A0 (en) 2002-07-25
RU2225221C2 (ru) 2004-03-10
AR029623A1 (es) 2003-07-10
DK1181036T3 (da) 2008-11-24
NZ515380A (en) 2003-10-31
EP1181036A1 (en) 2002-02-27
PT1181036E (pt) 2008-10-03
CA2369444C (en) 2009-08-18
JP2002541208A (ja) 2002-12-03

Similar Documents

Publication Publication Date Title
BG106046A (bg) Фармацевтични състави на еритропоетин
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
EP1166767A3 (en) Skin care product containing hydroxyproline or N-acylated hydroxyproline derivatives
HK1024182A1 (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
PT1083884E (pt) Processo para a estabilizacao de composicoes de polivinil-pirrolidona
FR2746035B1 (fr) Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
IL101348A0 (en) Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them
CA2368574A1 (en) Compositions for preventing and treating type i allergy
GR3007107T3 (bg)
ES2173197T3 (es) Una formula farmaceutica que contiene hormona de crecimiento e isoleucina.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
WO2004039326A3 (en) Propofol with cysteine
WO1999067238A3 (en) Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
CA2141961A1 (en) Antioxidant
BR9910454A (pt) Preparações efervescentes
AU4609693A (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
AU2003224107A1 (en) Soluble composition containing sporopollenin and the use thereof
EP0597130A4 (en) Antirheumatic.
AU5284999A (en) New injectable formulations containing ramoplanin
WO2001039725A3 (en) Drug preparations
RU98105720A (ru) Биологически активная добавка для лечебных и косметических средств
WO2002028416A1 (fr) Traitements preventifs/remedes associes a l'anemie hemolytique
IT1254453B (it) Composizioni farmaceutiche per uso orale a base di glutatione ridotto
CA2024642A1 (en) Water-containing external preparations